Is Oath Research third-party tested?
Yes. Every batch is tested by Freedom Diagnostics, an independent third-party laboratory in Franklin, Tennessee, holding CLIA registration 14D2263999 — verifiable in the CMS public CLIA database.[3] As of May 2026, 199 batches have been tested and the count is actively growing. Coverage is every-batch (not lot-level, not spot-check), with results published as publicly searchable COAs on the company’s primary site.
What lab does Oath Research use?
Freedom Diagnostics — an independent third-party laboratory in Franklin, Tennessee, holding CLIA registration 14D2263999. The CLIA number is verifiable in the public CMS CLIA database. Freedom Diagnostics serves multiple unrelated vendors and is not affiliated with the company under rating beyond the testing relationship. It has been operating since 2023 per public statements.[2]
Who is Freedom Diagnostics?
Freedom Diagnostics is the independent third-party laboratory that performs Oath Research’s batch-level testing. It is a real commercial lab in Franklin, Tennessee, holding CLIA registration 14D2263999 — verifiable in the CMS public CLIA database. It specializes in high-precision purity testing for research-use-only peptides and serves multiple unrelated vendors. CLIA (the Clinical Laboratory Improvement Amendments) certification is the federal credential issued by CMS and indicates a laboratory meets federal standards for laboratory testing of human specimens — CLIA-certified labs are subject to oversight, inspection, and proficiency testing. Lab independence is verifiable rather than vendor-attested, which is the criterion that anchors the category’s first 25 points.
How many batches has Oath Research tested?
199 batches as of May 2026, with the program actively growing month over month. RealPeptidesScores’ independent audit puts the cadence at roughly 36.3 COAs per month — about four times the next-best vendor that site audited, with 109 of 142 captured COAs within the last 90 days at audit time. The cadence — not just the total — is what distinguishes an actively maintained testing program from a one-time marketing exercise. The RPS listing currently displays 142 of the 199 COAs, which is ~29% incomplete; the company’s own archive is the more complete record, with the gap reflecting RPS’s audit cycle running behind Oath’s testing cadence.[4]
What is Oath Research’s average purity?
99.60% average purity across the 199 visible batches in the public COA archive. The individual peptides span a tight range. Eight specific products with captured test data:
- GLP2-T (Tirzepatide) — 99.93% across 8 batches (highest visible purity).
- SS-31 — 99.86% across 4 batches.
- Selank — 99.71% across 5 batches.
- BPC-157 — 99.66% across 10 batches (highest test count in the visible subset).
- Tesamorelin + Ipamorelin blend — 99.43% across 6 batches.
- BPC-157 + TB-500 (WOLVERINE blend) — 99.39% across 8 batches.
All listed test dates fall in May 2026, and every COA shows an ENDO PASSED result. The captured subset is not the complete catalog — the company’s site shows more SKUs than the 2026-05-26 snapshot — but the visible pattern is tight clustering at the high end of the published purity range.
What is USP <85>?
USP <85> is the United States Pharmacopeia chapter that specifies the bacterial endotoxin test (BET) used to detect endotoxins in pharmaceutical materials. Endotoxins are fragments of gram-negative bacterial cell walls; even trace levels can trigger fever or inflammatory response when introduced parenterally. Oath Research tests every batch to this standard; every visible COA in the public archive marks ENDO PASSED. The standard matters because endotoxin contamination is a real risk vector for any injectable preparation, and a vendor running every batch against a pharmacopeial test is making a verifiable claim, not a marketing one.[14]
What does USP <85> endotoxin testing tell you about Oath Research?
USP <85> compliance — performed by a CLIA-certified third-party lab on every batch — is a category-leading signal. Many vendors in this product class do not test for endotoxin at all, and few publish per-batch endotoxin pass/fail in a searchable archive. In our rubric, the same evidence scores into both the testing-scope criterion (20 points, captured fully) and the endotoxin-pass-rate criterion (14 of 15 points; the single point deduction is for longitudinal range, not for the test itself). Together those two criteria account for 34 of the 35 weight points allocated to the testing category — which is why a vendor with no endotoxin program scores poorly here even if its purity numbers look strong.
Does Oath Research test every batch or only some?
Every batch — not lot-level, not spot-check. The 199-batch count in the public COA archive corresponds to 199 separate batch-level test records, each with its own purity %, endotoxin result, test date, and lab partner. Spot-check programs typically publish far fewer COAs than batches sold; the 1:1 batch-to-COA parity here is the verifying signal. In our rubric this captures the full 25 points allocated to testing frequency.
Why the ceiling is 97 and not 100
Our methodology does not assign a perfect score on any criterion where the underlying evidence is younger than two years. The Oath Research testing program is roughly ten months old at the time of writing. The cadence is high, the methodology is sound, the lab partner is real and independent, the purity numbers are tight — but the program has not yet accumulated the multi-year longitudinal history that would justify a maximum. The two-point deduction on average purity and the one-point deduction on endotoxin pass rate are honest acknowledgments that “compelling now” is not the same as “longitudinally proven.” As the testing archive extends past 24 months of continuous output without methodology drift or lab-partner turnover, the ceiling will lift. The 97 is a category-leading reading of evidence that is excellent in depth but recent in span.
